Search Medical Condition
Please enter condition
Please choose location

Wien, Austria Clinical Trials

A listing of Wien, Austria clinical trials actively recruiting patients volunteers.

RESULTS

Found (347) clinical trials

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

The purpose of this study is to determine whether Etrasimod (APD334) is a safe and effective treatment for ulcerative colitis.

Phase

0.0 miles

Learn More »

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml

A prospective, randomized, investigator-masked, crossover comparison; Ocular hypertension or glaucoma (XFG or POAG) patients and who consent to participate will be enrolled in this study Patients will be scheduled for a screening visit IOP assessment (IOP measurements at 08:30, 12:30 and 16:30 (1 hour). Patients who are on therapy at ...

Phase

0.0 miles

Learn More »

Study of Nutritional Suitability of a New Infant Formula for Term Infants

This is a growth study of full-term infants. The growth of infants fed the investigational formula will be compared with infants fed a control formula. A breastfeeding arm will be used as reference.

Phase N/A

0.0 miles

Learn More »

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembrolizumab will provide improved disease-free survival (DFS) versus placebo.

Phase

0.0 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study

The purpose of this study is to prospectively evaluate acute and long term clinical results of orbital atherectomy (OA) with adjunctive drug coated balloon (DCB) angioplasty versus DCB angioplasty alone for treatment of Peripheral Artery Disease (PAD) in below the knee (BTK) lesions.

Phase N/A

0.0 miles

Learn More »

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

This study is designed as a prospective, randomized, multi-center trial. Data will be collected at enrollment, baseline, implant procedure, patient classification, 6 months and 12 months of follow-up. During the 6-month visit, the patient's response to CRT will be evaluated according to LVESV reduction. Patients with an LVESV reduction of ...

Phase N/A

0.0 miles

Learn More »

Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension

This study is a sham controlled, double blind study of subjects with uncontrolled hypertension consisting of two arms, sham and therapy. Bilateral renal denervation will be performed non-invasively using the Kona Medical Surround Sound System which delivers focused ultrasound therapy to ablate the nerves surrounding the renal artery utilizing real ...

Phase N/A

0.0 miles

Learn More »

Treatment of SFA Lesions With 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System

The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable scaffold and a delivery system used in the treatment of superficial femoral artery disease.

Phase N/A

0.0 miles

Learn More »

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

The investigational medicinal product denosumab is a protein (monoclonal antibody) that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis). Denosumab is used in adults with cancer to prevent serious complications caused by bone metastasis (e.g. fracture, pressure on the spinal cord or the ...

Phase

0.0 miles

Learn More »